An Open-label, Multi-center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler® Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old.
Phase of Trial: Phase III
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 18 Mar 2009 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 24 Jan 2008 The expected completion date for this trial is now 1 Nov 2008.